Neuronetics (NASDAQ:STIM) Lowered to Sell Rating by Wall Street Zen

Neuronetics (NASDAQ:STIM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other equities research analysts also recently weighed in on STIM. Canaccord Genuity Group reduced their target price on Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.00.

Neuronetics Price Performance

Shares of NASDAQ:STIM opened at $1.45 on Friday. The firm has a 50 day moving average of $1.60 and a 200-day moving average of $2.03. Neuronetics has a 12 month low of $0.80 and a 12 month high of $5.05. The company has a current ratio of 2.02, a quick ratio of 2.09 and a debt-to-equity ratio of 2.51. The stock has a market capitalization of $100.45 million, a PE ratio of -2.46 and a beta of 0.87.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. Neuronetics had a negative net margin of 26.15% and a negative return on equity of 121.26%. The business had revenue of $41.78 million for the quarter, compared to analyst estimates of $40.84 million. On average, equities research analysts predict that Neuronetics will post -1.13 EPS for the current fiscal year.

Insider Transactions at Neuronetics

In other news, major shareholder Jorey Chernett bought 607,400 shares of the stock in a transaction on Wednesday, March 18th. The stock was acquired at an average price of $1.35 per share, with a total value of $819,990.00. Following the acquisition, the insider directly owned 8,123,804 shares in the company, valued at approximately $10,967,135.40. This trade represents a 8.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Keith J. Sullivan sold 40,976 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $1.55, for a total value of $63,512.80. Following the completion of the transaction, the chief executive officer owned 1,567,012 shares of the company’s stock, valued at $2,428,868.60. This represents a 2.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders acquired 1,588,400 shares of company stock valued at $2,034,450 and sold 104,307 shares valued at $164,097. 8.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neuronetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. David J Yvars Group lifted its holdings in shares of Neuronetics by 22.1% during the fourth quarter. David J Yvars Group now owns 31,230 shares of the company’s stock worth $43,000 after purchasing an additional 5,650 shares during the period. National Bank of Canada FI raised its position in Neuronetics by 27.5% during the 3rd quarter. National Bank of Canada FI now owns 31,880 shares of the company’s stock worth $87,000 after purchasing an additional 6,880 shares during the last quarter. Royal Bank of Canada lifted its holdings in Neuronetics by 17.7% during the 4th quarter. Royal Bank of Canada now owns 47,233 shares of the company’s stock worth $65,000 after buying an additional 7,099 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Neuronetics in the 2nd quarter valued at about $34,000. Finally, Barclays PLC grew its position in shares of Neuronetics by 19.2% in the 4th quarter. Barclays PLC now owns 61,606 shares of the company’s stock valued at $85,000 after buying an additional 9,941 shares during the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.